Parathyroid Hormone as a Treatment for Osteoporosis

Today's Therapeutic Trends

Volumn 21, Issue 4, 2003, Pages 345-372

  Buxton, Eric C ^a   Fitzgerald, Iljie Kim ^a   Lane, Nancy E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 2; CALCITONIN; CALCIUM; CYTOKINE; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OSTEOGENIC PROTEIN 1; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C; STRONTIUM; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VITAMIN D;

ARTHRALGIA; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMUR NECK; FRAGILITY FRACTURE; HEADACHE; HORMONE SUBSTITUTION; HUMAN; LEG CRAMP; LUMBAR SPINE; NAUSEA; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; REVIEW; VERTEBRA FRACTURE;

EID: 0242299664     PISSN: 07412320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Tuck SP and Francis RM: Osteoporosis. Postgraad. Med. J. 78:526-532, 2002.
2. Delaney MF and LeBoff MS: Metabolic bone disease. In: Ruddy S, Harris ED, Sledge CB (Eds.). Kelley's Textbook of Rheumatology, 6th ed. WB Saunders, Philadelphia, PA, 2001, pp. 1635-1645.
3. Nevitt MC: Epidemiology of osteoporosis. Rheum. Dis. Clin. North Am. 20:535-559, 1994.
4. Dunlop MBV and Lane NE: Osteoporosis: Diagnosis, prevention, and treatment of established disease. Bull. Rheum. Dis. 48(6):1-4, 1999.
5. Teegarden D, Proulx WR, Martin BR, et al.: Peak bone mass in young women. J. Bone Miner. Res. 10(5):711-715, 1995.
6. Takahashi N, Udagawa N, Takami M, et al.: Cells of bone, osteoclast generation. In: Bilezikian JP, Raisz LG, Rodan GA (Eds.). Principles of Bone Biology, 2nd Ed. Academic Press, San Diego, CA, 2002, pp. 109-126.
7. Vaananen K and Zhao H: Osteoclast function, biology and mechanisms. In: Bilezikian JP, Raisz LG, Rodan GA (Eds.). Principles of Bone Biology, 2nd Ed. Academic Press, San Diego, CA, 2002, pp. 127-139.
8. Lane NE and Rehman Q: Osteoporosis in the rheumatic disease patient. Lupus 11(10):675-679, 2002.
9. Khosla S: Minireview: The OPG/RANKL/RANK system. Endocrinology 142(12):5050-5055, 2001.
10. Jilka RL: Biology of the basic multicellular unit and the pathophysiology of osteoporosis. Med. Pediatr. Oncol. 41(3):182-185, 2003.
11. Martens MG: Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. J. Reprod. Med. 48(6):425-434, 2003.
12. Eastell R: Treatment of postmenopausal osteoporosis. N. Engl. J. Med. 338(11):736-746, 1998.
13. Harris ST, et al., for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA 282(14):1344-1353, 1999.
14. Black DM, Cummings SR, Karpf DB, et al., for the Fracture Intervention Trial Research Group: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541, 1996.
15. Cummings SR, Black DM, Thompson DE, et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280:2077-2082, 1998.
16. Ettinger B, Black DM, Mitlak BH, et al., for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 282:637-645, 1999.
17. O'Regan RM and Gradishar WJ: Selective estrogen-receptor modulators in 2001. Oncology (Huntingt.) 15(9):1177-1185, 2001.
18. Chesnut CH III, Silverman S, Andriano K, et al., for the PROOF Study Group: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study. Am. J. Med. 109:267-276, 2000.
19. Rubin MR and Bilezikian JP: New anabolic therapies in osteoporosis. Endocrinol. Metab. Clin. North Am. 32(1):285-307, 2003.
20. Lane NE and Kelman A: A review of anabolic therapies for osteoporosis. Arthritis Res. Ther., 2003 (in press).
21. Yakar S and Rosen CJ: From mouse to man: Redefining the role of insulin-like growth factor-I in the acquisition of bone mass. Exp. Biol. Med. (Maywood) 228(3):245-252, 2003.
22. Rosen T, Wilhelmsen L, Landin-Wilhelmsen K, et al.: Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur. J. Endocrinol. 137(3):240-245, 1997.
23. Thrailkill KM, Siddhanti SR, Fowlkes JL and Quarles LD: Differentiation of MC3T3-E1 osteoblasts is associated with temporal changes in the expression of IGF-I and IGFBPs. Bone 17(3):307-313, 1995.
24. Reginster JY: Strontium ranelate in osteoporosis. Curr. Pharm. Des. 8(21):1907-1916, 2002.
25. Marie PJ: Effects of strontium on bone formation and bone cells. In: Neve J (Ed.). Therapeutic Use of Trace Elements. Plenum Press, New York, 1996, pp. 277-282.
26. Reginster JY, Deroisy R, Dougados M, et al.: Prevention of early postmenopausal bone loss by strontium ranelate: The randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos. Int. 13(12):925-931, 2002.
27. Reginster JY and Meunier PJ: Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Osteoporos. Int. 14(Suppl. 3):S56-S65, 2003.
28. Mundy G, Garrett R, Harris S, et al.: Stimulation of bone formation in vitro and in rodents by statins. Science 286(5446):1946-1949, 1999.
29. van Staa TP, Wegman S, de Vries F, et al.: Use of statins and risk of fractures. JAMA 285(14):1850-1855, 2001.
30. Reid IR, Hague W, Emberson J, et al.: Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 357(9255):509-512, 2001.
31. LaCroix AZ, Cauley JA, Pettinger M, et al.: Statin use, clinical fracture, and bone density in postmenopausal women: Results from the Women's Health Initiative Observational Study. Ann. Intern. Med. 139(2):97-104, 2003.
32. Saadeh PB, Mehrara BJ, Steinbrech DS, et al.: Transforming growth factor-beta1 modulates the expression of vascular endothelial growth factor by osteoblasts. Am. J. Physiol. 277(4, Pt. 1):C628-C637, 1999.
33. Nagai H, Tsukuda R and Mayahara H: Effects of basic fibroblast growth factor (bFGF) on bone formation in growing rats. Bone 16(3):367-373, 1995.
34. Lane NE, Kumer J, Yao W, et al.: Basic fibroblast growth factor forms new trabeculae that physically connect with pre-existing trabeculae, and this new bone is maintained with an anti-resorptive agent and enhanced with an anabolic agent in an osteopenic rat model. Osteoporos. Int. 14(5):374-382, 2003.
35. Street J, Bao M, deGuzman L, et al.: Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc. Natl. Acad. Sci. U S A 99(15):9656-9661, 2002.
36. Wang EA, Israel DI, Kelly S and Luxenberg DP: Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells. Growth Factors 9(1):57-71, 1993.
37. Ahrens M, Ankenbauer T, Schroder D, et al.: Expression of human bone morphogenetic proteins-2 or -4 in murine mesenchymal progenitor C3H10T1/2 cells induces differentiation into distinct mesenchymal cell lineages. DNA Cell Biol. 12(10):871-880, 1993.
38. Geesink RG, Hoefnagels NH and Bulstra SK: Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. J. Bone Joint Surg. Br. 81(4):710-718, 1999.
39. Li J, Duncan RL, Burr DB and Turner CH: Parathyroid hormone enhances mechanically induced bone formation through activation of L-type voltage-sensitive calcium channels. Presented at the 24th Annual Meeting of the American Society for Bone and Mineral Research, September 20-24, 2002, San Antonio, TX.
40. Watson PH, Kisiel M, Patterson EK, et al.: Expression of Type I PTH/ PTHrP receptors in the rat osteoclast and osteoclast-like RAW 264.7 cells. Presented at the 24th Annual Meeting of the American Society for Bone and Mineral Research, September 20-24, 2002, San Antonio, TX.
41. Silverberg SJ, Shane E, de la Cruz L, et al.: Skeletal disease in primary hyperparathyroidism. J. Bone Min. Res. 4:283, 1989.
42. Ejersted C, Andreassen TT, Oxlund H, et al.: Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats. J. Bone Miner. Res. 8(9):1097-1101, 1993.
43. Divieti P, Inomata N, Chapin K, et al.: Receptors for the carboxyl-terminal region of PTH(1-84) are highly expressed in osteocytic cells. Endocrinology 142(2):916-925, 2001.
44. Inomata N, Akiyama M, Kubota N and Juppner H: Characterization of a novel parathyroid hormone (PTH) receptor with specificity for the carboxyl-terminal region of PTH-(1-84). Endocrinology 136(11):4732-4740, 1995.
45. Takasu H, Baba H, Inomata N, et al.: The 69-84 amino acid region of the parathyroid hormone molecule is essential for the interaction of the hormone with the binding sites with carboxyl-terminal specificity. Endocrinology 137(12):5537-5543, 1996.
46. Murray TM, Rao LG and Muzaffar SA: Dexamethasone-treated ROS 17/2.8 rat osteosarcoma cells are responsive to human carboxylterminal parathyroid hormone peptide hPTH (53-84): Stimulation of alkaline phosphatase. Calcif. Tissue Int. 49(2):120-123, 1991.
47. Dambacher MA, Fischer JA, Hunziker WH, et al.: Distribution of circulating immunoreactive components of parathyroid hormone in normal subjects and in patients with primary and secondary hyperparathyroidism: The role of the kidney and of the serum calcium concentration. Clin. Sci. (Lond.) 57(5):435-443, 1979.
48. Divieti P, Lotz O, Geller A, et al.: Inhibition of osteoclast formation by human PTH(7-84) involves direct actions on hematopoietic cells. Presented at the 24th Annual Meeting of the American Society for Bone and Mineral Research, September 20-24, 2002, San Antonio, TX.
49. Bauer W, Aub JC and Albright F: Studies of calcium phosphorus metabolism: Study of bone trabeculae as ready available reserve supply of calcium. J. Exp. Med. 49:145-162, 1929.
50. Selye H: On the stimulation of new bone-formation with parathyroid extract, irradiated ergosterol. Endocrinology 16:547-558, 1932.
51. Pugsley LI and Selye H: The histological changes in the bone responsible for the action of parathyroid hormone on the calcium metabolism of the rat. J. Physiol. (Lond.) 79:113-117, 1933.
52. Jilka RL, Weinstein RS, Bellido T, et al.: Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest. 104:439-446, 1999.
53. Nishida S, et al.: Increased bone formation by intermittent parathyroid hormone administration is due to stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone 15:717-723, 1994.
54. MacDonald BR, et al.: Parathyroid hormone stimulates the proliferation of cells derived from human bone. Endocrinology 118:2445-2449, 1986.
55. Onishi T, et al.: The mitogenic effect of parathyroid hormone is associated with E2F-dependent activation of cyclin-dependent kinase 1 (cdc2) in osteoblast precursors. J. Bone Miner. Res. 12:1596-1605, 1997.
56. Dobnig H, et al.: Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136:3632-3638, 1995.
57. Leaffer D, et al.: Modulation of osteogenic cell ultrastructure by RS-23581, an analog of human parathyroid hormone (PTH)-related peptide-(1-34), and bovine PTH-(1-34). Endocrinology 136:3624-3631, 1995.
58. Jerome CP: Anabolic effect of high doses of human parathyroid hormone (1-38) in mature intact female rats. J. Bone Miner. Res. 9(6):933-942, 1994.
59. Toromanoff A, Ammann P and Riond JL: Early effects of short-term parathyroid hormone administration on bone mass, mineral content, and strength in female rats. Bone 22(3):217-223, 1998.
60. Hori M, et al.: Effect of human parathyroid hormone (PTH (1-34)) on experimental osteopenia of rats induced by ovariectomy. J. Bone Miner. Res. 3(3):193-199, 1988.
61. Sato M, Zeng GQ and Turner CH: Biosynthetic human parathyroid hormone (1-34). Effects on bone quality in aged ovariectomized rats. Endocrinology 138(10):4330-4337, 1997.
62. Ejersted C, et al.: Parathyroid hormone (1-34) increases vertebral bone mass, compressive strength, and quality in old rats. Bone 17(6):507-511, 1995.
63. Hock JM, Gera I, Fonseca J and Raisz LG: Human parathyroid hormone-(1-34) increases bone mass in ovariectomized and orchidectomized rats. Endocrinology 122:2899-2904, 1988.
64. Oxlund H, Dalstra M, Ejersted C and Andreassen TT: Parathyroid hormone induces formation of new cancellous bone with substantial mechanical strength at a site where it had disappeared in old rats. Eur. J. Endocrinol. 146(3):431-438, 2002.
65. Lindsay R, Hodsman AB, Genant HK, et al.: A randomized controlled multicenter study of 1-84 hPTH for treatment of postmenopausal osteoporosis. Bone 23(Suppl. 1):S175, 1998.
66. Rittmaster RS, et al.: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J. Clin. Endocrinol. Metab. 344:1434-1441, 2000.
67. Fujita T, et al.: Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: A randomized double-masked prospective study using three dose levels. Osteoporos. Int. 9:296-306, 1999.
68. Hodsman AB, et al.: A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 82(2):620-628, 1997.
69. Finkelstein JS, et al.: Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34). A randomized controlled trial. JAMA 280:1067-1073, 1998.
70. Neer RM, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344(19):1434-1441, 2001.
71. Forteo™ prescribing information. Eli Lilly and Company. Available at: www.LillyMedical.com.
72. Lindsay R, et al.: Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550-555, 1997.
73. Dempster DW, et al.: Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J. Bone Miner. Res. 16(10):1846-1853, 2001.
74. Cosman F, et al.: Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J. Bone Miner. Res. 16(5):925-931, 2001.
75. Roe EB, et al.: Parathyroid hormone 1-34 (hPTH 1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis-Results from a placebo-controlled randomized trial. J. Bone Miner. Res. 14(Suppl. 1):S137, 1999.
76. Neer R, Hayes A, Rao A and Finkelstein J: Effects of parathyroid hormone, alendronate, or both on bone density in osteoporotic postmenopausal women. Presented at the 24th Annual Meeting of the American Society for Bone and Mineral Research, September 20-24, 2002, San Antonio, TX.
77. Black DM, et al.: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349(13):1207-1215, 2003.
78. Ray NF, Chan JK, Thamer M and Melton LJ III: Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation. J. Bone Miner. Res. 12:24-35, 1997.
79. Gullberg B, Ohnell O and Kanis JA: World-wide projections for hip fracture. Osteoporos. Int. 7:407-413, 1997.
80. O'Neill TW, Felsenberg D, Varlow J, et al.: The prevalence of vertebral deformity in European men and women: The European Vertebral Osteoporosis Study. J. Bone Miner. Res. 11:1010-1018, 1996.
81. Orwoll E, et al.: Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med. 343(9):604-610, 2000.
82. Slovik DM, Rosenthal DI, Doppelt SH, et al.: Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J. Bone Miner. Res. 1:377-381, 1986.
83. Reeve J, Meunier PJ, Parsons JA, et al.: Anabolic effect of human parathroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial. Br. Med. J. 280:1340-1344, 1980.
84. Kurland ES, et al.: Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers. J. Clin. Endocrinol. Metab. 85(9):3069-3076, 2000.
85. Orwoll ES, et al.: The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J. Bone Miner. Res. 18(1):9-17, 2003.
86. Finkelstein S, et al.: Effects of parathyroid hormone, alendronate, or both on bone density in osteoporotic men. Abstract presented at the 24th Annual Meeting of the American Society for Bone and Mineral Research, September 20-24, 2002, San Antonio, TX.
87. Finkelstein JS, et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. 349(13):1216-1226, 2003.
88. Lane NE, Sanchez S, Modin GW, et al.: Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J. Clin. Invest. 102(8):1627-1633, 1998.